TSP-2-null ECM Hydrogel for Tunable Regenerative Scaffolds
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current regenerative materials face challenges in customizability and tunability, particularly with decellularized extracellular matrices (ECM), which are difficult to engineer for specific applications due to their natural source dependence and limited control over architecture and mechanics, and lack effective methods for generating tunable acellular matrices for regenerative medicine.
Innovation Solution
A method involving the use of a decellularized extracellular matrix lacking thrombospondin-2 (TSP-2-null ECM) derived from primary matrix-producing cells, formulated as a hydrogel, to enhance cellular migration, vascular growth, and wound repair by administering it to treatment sites, either subcutaneously or topically, and combining it with therapeutic agents for improved tissue regeneration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If decellularized materials are used as regenerative scaffolds, then biocompatibility and native ECM structure are improved, but customizability and engineering control are worsened
Solution Approach 1:
The patent applies parameter changes by genetically manipulating cells to alter TSP-2 expression levels, thereby changing the biochemical composition parameters of the ECM. This allows customization of the matrix properties while maintaining the native decellularized structure, resolving the contradiction between biocompatibility and adaptability
Solution Approach 2:
The patent creates a customized copy of the natural ECM by having cells produce a modified version of the extracellular matrix with altered TSP-2 content. This copied matrix retains the native structure and biocompatibility while incorporating the desired genetic modifications for enhanced customizability
2Adaptability or versatility
If genetic manipulation is used to alter ECM production, then tunability of ECM composition is improved, but process complexity and understanding requirements are worsened
Solution Approach 1:
The patent extracts and focuses on a single key parameter - TSP-2 expression - as the primary genetic manipulation target. By isolating this specific gene for modification rather than attempting comprehensive ECM control, the patent achieves tunability while minimizing process complexity and making the system more tractable for understanding and application
Data Source
AI summary
The present invention relates in part to compositions and methods for treating a wound, or location of interest, in mammal by administering a decellularized extracellular matrix (ECM) lacking thrombospondin-2 (TSP-2-null ECM). In certain embodiments, the invention provides an acellular composition comprising a decellularized TSP-2-null ECM. In certain embodiments, the invention provides a tunable hydrogel comprising a decellularized TSP-2-null ECM. The invention also provides, in certain embodiments, methods for accelerating cellular migration, methods for enhancing cellular invasion, methods for enhancing vascular growth and maturation of a region to be treated, and/or methods for enhancing a wound repair in a mammal in need thereof.